Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
Colm Keane, Frank Vari, Mark Hertzberg, Kim-Anh Le Cao, Michael R Green, Erica Han, John F Seymour, Rodney J Hicks, Devinder Gill, Pauline Crooks, Clare Gould, Kimberley Jones, Lyn R Griffiths, Dipti Talaulikar, Sanjiv Jain, Josh Tobin, Maher K Gandhi
The Lancet Haematology | ELSEVIER SCI LTD | Published : 2015
Funding for this study was received from the Leukaemia Foundation of Queensland; the Kasey-Anne Oklobdzijato Memorial fund; the Australasian Leukaemia and Lymphoma Group (Malcolm Broomhead Bequest); the Australian Cancer Research Foundation; the Cancer Council of Queensland and Health and Medical Research Queensland. Roche provided funds towards clinical running of the ALLGNHL21 trial.